Literature DB >> 22865262

Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research.

Marie Hudson1, Russell Steele, Murray Baron.   

Abstract

Entities:  

Year:  2012        PMID： 22865262      PMCID： PMC3497900          DOI： 10.1007/s12079-012-0172-4

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN： 1873-9601            Impact factor:   5.782


× No keyword cloud information.
  24 in total

1.  Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures.

Authors:  Miguel A Hernán; Babette A Brumback; James M Robins
Journal:  Stat Med       Date:  2002-06-30       Impact factor: 2.373

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

3.  De testimonio: on the evidence for decisions about the use of therapeutic interventions.

Authors:  Michael Rawlins
Journal:  Lancet       Date:  2008-12-20       Impact factor: 79.321

4.  Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.

Authors:  Sotiris C Plastiras; Stylianos P Karadimitrakis; Panayiotis D Ziakas; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos; George E Tzelepis
Journal:  Arthritis Rheum       Date:  2006-08-15

Review 5.  Estimating causal effects from large data sets using propensity scores.

Authors:  D B Rubin
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

6.  The effect of D-penicillamine on pulmonary findings in systemic sclerosis.

Authors:  V D Steen; G R Owens; C Redmond; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1985-08

7.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

8.  The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study.

Authors:  Frank J Palella; Carl Armon; Kate Buchacz; Stephen R Cole; Joan S Chmiel; Richard M Novak; Kathleen Wood; Anne C Moorman; John T Brooks
Journal:  Ann Intern Med       Date:  2009-07-21       Impact factor: 25.391

Review 9.  Measuring disease activity and severity in scleroderma.

Authors:  P J Clements
Journal:  Curr Opin Rheumatol       Date:  1995-11       Impact factor: 5.006

10.  African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.

Authors:  E L Greidinger; K T Flaherty; B White; A Rosen; F M Wigley; R A Wise
Journal:  Chest       Date:  1998-09       Impact factor: 9.410
View more
  2 in total

1.  Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.

Authors:  Sabrina Hoa; Sasha Bernatsky; Russell J Steele; Murray Baron; Marie Hudson
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

2.  Long-term effects of immunosuppressive therapy on lung function in scleroderma patients.

Authors:  Slavica Pavlov-Dolijanovic; Nada Vujasinovic Stupar; Vladimir Zugic; Predrag Ostojic; Ana Zekovic; Tatjana Zivanovic Radnic; Ivan Jeremic; Ivana Tadic
Journal:  Clin Rheumatol       Date:  2018-08-24       Impact factor: 2.980
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.